The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics ...
Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections. CANTON, Mass.–(BUSINESS WIRE)–December 10, 2024– Orthogon Therapeutics, a developer of novel antiviral ...
Single-cell analysis helps uncover how the BK virus replicates, opening the door to new drug targets. BK polyomavirus (BKPyV) is a major cause of kidney transplant failure. Without a complete ...
A virus that 95% of adults carry from childhood infections may be initiating bladder cancer decades later, according to research from the University of York and collaborating institutions. BK ...
Presenter: Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, U.K. About MAU868 MAU868, a first-in-class monoclonal antibody, has the potential to ...
Research published in the Journal of Infection investigated the use of metagenomic next-generation sequencing (mNGS) in diagnosing bloodstream infections (BSIs) for immunocompromised hematology ...
CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results